About US
Contact us
-
2022 forecast: With omicron extending the pandemic, how will biopharma respond to COVID?Think back to this time last year. Remember the uncertainty the COVID-19 pandemic posed? Well, thanks to omicron, here we are again, asking many of the same questions and with renewed anxiety about t2021/12/20
-
2022 forecast: Cell, gene therapy makers push past regulatory, payer hurdles to set up high hopes for next yearFor developers of cell and gene therapies, the path to market often seems to be marred with potholes. The FDArejectedBioMarin Pharmaceutical’s gene therapy to treat hemophilia A in 2020, citing the n2021/12/20
-
Novartis launches $15B share buyback after huge windfall from Roche stake sale—but M&A is still in the cardsNovartis has found a way to spend the big pile of cash—at least $15 billion of it—the drugmaker received from selling a large stake in Swiss rival Roche. Novartis isinitiatinga share buyback campa2021/12/17
-
Biogen hits the gas pedal on Aduhelm confirmatory trial, hoping to deliver results in 2026Biogen is looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer’s disease drug Aduhelm out in four years, as the fate of this drug, and Biogen itself, rests in the ba2021/12/17
-
As part of $800M investment, Pfizer opens gene therapy facility in NC for early-stage productionPfizer is betting big on gene therapy development and manufacturing. And to that end, it is centralizing its operations in—where else—North Carolina. These days in the biopharma industry,2021/12/15
-
In its old age, Bristol Myers' Orencia becomes first drug approved for preventing graft-versus-host diseaseIn its twilight, Bristol Myers Squibb’s Orencia is putting together an impressive second act. The rheumatoid arthritis drug—originally approved in 2005—got a nice bump in 2017 with an approval for ps2021/12/15
-
Sayonara, San Francisco. #JPM22 is going virtual, thanks to COVIDCancelled flights and hotel rooms have become par for the course during the COVID-19 pandemic. Now, with less than a month to go until the J.P. Morgan healthcare conference in January, the event orga2021/12/13
-
Eli Lilly trots out rosy 2022 projections, sees recent launches driving two-thirds of its businessEli Lilly said happy holidays to its shareholders on Wednesday morning,bumpingup its revenue projections for this year and next. While the top-line numbers bested analyst expectations, the company al2021/12/13
-
After its $7.6B buyout fell through, Sobi scores NICE backing for rare disease drug AspaveliAfter rare disease drugmaker Sobi reportedly had a buyoutscupperedby pharma giant AstraZeneca, the company has picked up a win that stands to bolster its Aspaveli launch. England's National Institute2021/12/10
-
AstraZeneca's Evusheld becomes first FDA-authorized COVID antibody to protect the immunocompromised before exposurePeople in the U.S. with conditions that prevent them from building immunity with COVID-19 vaccines will soon have a way to get adequate protection from the virus. With the FDA’s emergency2021/12/10